COVID-19

Since last December 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was reported in Wuhan, China. COVID-19 has subsequently affected the global regions including Americas, Europe, Africa, Western Pacific, etc. Even though COVID-19 is an acute resolved disease, it can also be deadly, with a 2% case fatality rate. As of Mar 18, about 191,127 cases have been confirmed globally, with 7807 death cases. Now COVID-19 is an emerging, rapidly evolving situation.

COVID-19 Patients’ Immune Response

A study just published in Nature Medicine reported the breadth of concomitant immune responses prior to one COVID-19 patient recovery, showing the body’s ability to fight against SARS-CoV-2 and recover from the infection. Scientists collected blood samples to study how the patient’s immune responses performed, and when the immune system activated. They found that increased antibody-secreting cells (ASCs), follicular helper T cells (T_FH cells), activated CD4⁺ T cells and CD8⁺ T cells and immunoglobulin M (IgM) and IgG antibodies which react with COVID-19-causing coronavirus SARS-CoV-2 were detected in blood before symptomatic recovery. These immune activities persisted for at least 7 days after the infection went away.

COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development

The published data provided evidence on the recruitment of a variety of immune cell populations, together with IgM and IgG SARS-CoV-2 binding antibodies in the patient’s blood before the resolution of symptoms, providing insights into the potential therapeutic antibody therapy to treat COVID-19. With extensive experiences and knowledge in antibody discovery and development, Creative Biolabs is confident in the anti-SARS-CoV-2 therapeutic antibody development program using blood samples from COVID-19 recovered patients. Empowered by Native™ Antibody Discovery and B cell sorting platform, we have been providing the quality native paired antibodies for over 10 years. Creative Biolabs can assist companies and academic investigators who are actively developing COVID-19 therapy with our Native™ Antibody Discovery platform.

Fig.1 Proposed immune responses during SARS-CoV-2 infection.¹

Highlights

• End-to-end solutions for COVID-19 therapy discovery and development
• Antibody and immunotherapy Expert
• Extensive experiences

Creative Biolabs is seeking partners to co-develop the therapeutic monoclonal antibody program targeting SARS-CoV-2. As always, we are available for flexible discussions to see how we can collaborate and develop the research against COVID-19. Please don’t hesitate to contact us by email, telephone, or TC when you have any questions. Let’s work together to find solutions to this novel virus.

Reference

1. Manfrini, Nicola, et al. "SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination." Antibodies 13.1 (2024): 13. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use